Blog
RSS FeedPosted by Michael Wonder on 12 Jul 2016
Governments need better guidance to maximise value for money: the case of Australia’s Pharmaceutical Benefits Advisory Committee
12 July 2016 - In Australia, the PBAC makes recommendations to the Minister for Health on which pharmaceuticals should be ...
Posted by Michael Wonder on 11 Jul 2016
SMC gives green light for BMS’ Opdivo
11 July 2016 - Scotland will be first UK country to access the drug after NICE refusal. ...
Posted by Michael Wonder on 11 Jul 2016
SMC - July 2016 decisions
11 July 2016 - Two new medicines for lung cancer among five treatments accepted for routine use in NHS Scotland. ...
Posted by Michael Wonder on 11 Jul 2016
Uncertainty for Masterton mother after drug trial ditched
11 July 2016 - Masterton mother of three Allyson Lock is one of 11 Kiwis with Pompe disease, a rare and ...
Posted by Michael Wonder on 09 Jul 2016
'Cancer drug that the NHS refuses to pay for brought me back from the dead'
9 July 2016 - Simon Lamont-Brown returned home within weeks of taking nivolumab after being given days to live in a ...
Posted by Michael Wonder on 09 Jul 2016
Drug that cures rare disease hereditary tyrosinaemia type 1 gets approval on Life Saving Drugs Program
9 July 2016 - Six weeks after the birth of their daughter Jeanette in 2001, Melbourne couple Faye and Youssef Azer ...
Posted by Michael Wonder on 08 Jul 2016
NHS England, PTC reach agreement on Duchenne drug
8 July 2016 - Children in England suffering from a rare form of muscular dystrophy will soon be able to access ...
Posted by Michael Wonder on 08 Jul 2016
The bottom line
8 July 2016 - t's hard to put a value on a human life. When you're well, perhaps you don't think ...
Posted by Michael Wonder on 08 Jul 2016
Japan's Eisai weighs legal action in UK cancer drug row
8 July 2016 - Japan's Eisai said on Friday it would consider all options, including possible legal action, to fight delays ...
Posted by Michael Wonder on 08 Jul 2016
Rare Cancers Australia lodges PBAC submission
8 July 2016 - Rare Cancers Australia has lodged a submission for the reimbursement of MSD's Zolinza (vorinistat) for cutaneous T-cell ...
Posted by Michael Wonder on 07 Jul 2016
NICE approves first drug from old Cancer Drugs Fund
7 July 2016 - Dozens of patients with leukaemia will now have an automatic right to the drug bosutinib rather than ...
Posted by Michael Wonder on 07 Jul 2016
Pfizer drug wins U.K. support following overhaul of Cancer Fund
7 July 2016 - Drug costs $58,000 a year before discounts from Pfizer. ...
Posted by Michael Wonder on 07 Jul 2016
Proposal to award sole supply to goserelin acetate (Zoladex) and reference price leuprorelin acetate (Eligard and Lucrin PDS)
7 July 2016 - PHARMAC has entered into a provisional agreement with AstraZeneca. ...
Posted by Michael Wonder on 06 Jul 2016
Charity calls on NICE to reverse Opdivo rejection
6 July 2016 - Kidney Cancer UK is calling on the National Institute for Health and Care Excellence to reverse a ...
Posted by Michael Wonder on 06 Jul 2016
Saskatchewan includes Lemtrada (alemtuzumab) on MS Drugs Program for eligible patients
5 July 2016 - Unique treatment delivered in only two cycles one year apart. ...